Imran Haque's guest appearances

Imran Haque

Tech Tonics

ChildX: Child and Maternal Health

The Data Pulse

Matt Wilsey

Dennis Wall

Daphne Koller

Atul Butte

Stephanie Tilenius

Kyle Swanson

Dave Albert

Will Ahmed

Toby Cosgrove

Kevin Lyman

Madeline Bell

Carlos Bustamante

Rasu Shrestha

Brennan Spiegel

Matthew Holt

OwlTail

Conventional drug discovery ignores the spatial relationships between cells when assessing the effects of drugs. I talk with Imran Haque, VP of Data Science at Recursion Pharmaceuticals, about their data-first approach that combines "cell painting" with deep learning to assess changes in cellular morphology, thus providing a crucial lens into the molecular wirings of a given drug's mechanism of action. We discuss his team's work in repurposing therapies to tackle COVID-19 and what it takes to successfully merge deep learning with cellular images in a way that yields therapies. Check out the glossary of terms, definitions, and resources (and get a sneak peak of the future conversations lined up!) here: bit.ly/datapulse-glossary--- Support this podcast: https://podcasters.spotify.com/pod/show/the-data-pulse/support

Conventional drug discovery ignores the spatial relationships between cells when assessing the effects of drugs. I talk with Imran Haque, VP of Data Science at Recursion Pharmaceuticals, about their data-first approach that combines "cell painting" with deep learning to assess changes in cellular morphology, thus providing a crucial lens into the molecular wirings of a given drug's mechanism of action. We discuss his team's work in repurposing therapies to tackle COVID-19 and what it takes to successfully merge deep learning with cellular images in a way that yields therapies. Check out the glossary of terms, definitions, and resources (and get a sneak peak of the future conversations lined up!) here: <a href="https://anchor.fm/dashboard/episode/egftra/metadata/bit.ly/data-pulse-glossary" rel="ugc noopener noreferrer nofollow" target="_blank">bit.ly/datapulse-glossary</a>--- Support this podcast: <a href="https://podcasters.spotify.com/pod/show/the-data-pulse/support" rel="payment nofollow" target="_blank">https://podcasters.spotify.com/pod/show/the-data-pulse/support</a>

Phenomics + computer vision for drug discovery with Imran Haque (Recursion Pharma)

A computational biologist by training, Imran Haque has managed to achieve the near-impossible: embracing the promise of data science in medicine while retaining his critical faculties.  He may well be just the sort of innovator required at the intersection of medicine and big data. Born and raised in the Bay Area, Imran says he grew up in the sort of environment where his father, an electrical engineer, didn’t think twice, when Imran was in elementary school, about giving him a book about how to code – which he immediately devoured. Imran went to college at Berkeley (go Bears!), where he majored in electrical engineering and computer science, and developed an interest in computational biology.  He pursued this in graduate school in computer science at Stanford, where he was advised by such luminaries as computational biologist Vijay Pande (now a VC) and AI wizard Daphne Koller (a previous Tech Tonics guest, and the founder of insitro). Imran subsequently has forged the path at the intersection of biology and analytics, assuming roles of increasing prominence at Counsyl (focused on carrier screening) and Freenome (early identification of cancer).  In these roles he developed a reputation for rigorous and critical thinking, arguing that data suggest screening couples for many rare diseases represents a sensible idea, while screening healthy people for very early stage cancers by looking for circulating tumor DNA (ctDNA) may run up against physical limitations, namely the lack of a single disease molecule in the typical volume of blood sampled. In addition, as David has written in Forbes (see here, also here), Imran is excited about the opportunities associated with data and analytics in biology, but is wary about the seductive false positives powerful techniques tend to generate. Join us today for a captivating conversation from the untamed frontier of analytics in medicine and drug discovery. Today’s show is sponsored by IDEA pharma, the industry’s leading path-to-market strategy practice, bringing more great medicines to patients.  You can find them at: ideapharma.com.

A computational biologist by training, Imran Haque has managed to achieve the near-impossible: embracing the promise of data science in medicine while retaining his critical faculties.  He may well be just the sort of innovator required at the intersection of medicine and big data. Born and raised in the Bay Area, Imran says he grew up in the sort of environment where his father, an electrical engineer, didn’t think twice, when Imran was in elementary school, about giving him a book about how to code – which he immediately devoured. Imran went to college at Berkeley (go Bears!), where he majored in electrical engineering and computer science, and developed an interest in computational biology.  He pursued this in graduate school in computer science at Stanford, where he was advised by such luminaries as computational biologist <a href="https://pande.stanford.edu/" rel="nofollow" target="_blank">Vijay Pande</a> (now a VC) and AI wizard Daphne Koller (a <a href="https://venturevalkyrie.com/new-tech-tonics-podcast-daphne-koller-guiding-health-from-ai-to-actual-intelligence/" rel="nofollow" target="_blank">previous Tech Tonics guest</a>, and the founder of insitro). Imran subsequently has forged the path at the intersection of biology and analytics, assuming roles of increasing prominence at Counsyl (focused on carrier screening) and Freenome (early identification of cancer).  In these roles he developed a reputation for rigorous and critical thinking, <a href="https://jamanetwork.com/journals/jama/fullarticle/2544641" rel="nofollow" target="_blank">arguing</a> that data suggest screening couples for many rare diseases represents a sensible idea, while screening healthy people for very early stage cancers by looking for circulating tumor DNA (ctDNA) <a href="https://www.biorxiv.org/content/10.1101/237578v1" rel="nofollow" target="_blank">may run up against physical limitations</a>, namely the lack of a single disease molecule in the typical volume of blood sampled. In addition, as David has written in Forbes (see <a href="https://www.forbes.com/sites/davidshaywitz/2019/01/03/data-scientist-explains-how-ais-seductive-power-can-mislead-biomarker-researchers/" rel="nofollow" target="_blank">here</a>, also <a href="https://www.forbes.com/sites/davidshaywitz/2019/05/23/pharmas-desperate-struggle-to-teach-old-data-new-tricks/#34a25a4c3434" rel="nofollow" target="_blank">here</a>), Imran is excited about the opportunities associated with data and analytics in biology, but is wary about the seductive false positives powerful techniques tend to generate. Join us today for a captivating conversation from the untamed frontier of analytics in medicine and drug discovery. Today’s show is sponsored by IDEA pharma, the industry’s leading path-to-market strategy practice, bringing more great medicines to patients.  You can find them at: <a href="http://ideapharma.com/" rel="nofollow" target="_blank">ideapharma.com</a>.

Tech Tonics: Imran Haque, Grounded Data Scientist

Imran Haque – Precision Medicine for Rare Childhood Disease_ Stanford Childx Conference